Apixaban Safe for Kids’ Heart Thromboprophylaxis 03/21/26
Welcome to Cardiology Today – Recorded March 21, 2026. This episode summarizes 5 key cardiology studies on topics like coronary artery disease and Time-restricted eating. Key takeaway: Apixaban Safe for Kids’ Heart Thromboprophylaxis.
Article Links:
Article 1: Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study. (Journal of the American Heart Association)
Article 2: Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study. (Journal of the American Heart Association)
Article 3: Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction. (Journal of the American Heart Association)
Article 4: Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy. (Journal of the American Heart Association)
Article 5: Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry. (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/apixaban-safe-for-kids-heart-thromboprophylaxis-03-21-26/
📚 Featured Articles
Article 1: Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859904
Summary: A randomized-controlled crossover study investigated a two-week time-restricted eating intervention, allowing eating only between 8 a.m. and 2 p.m., in patients with a history of myocardial infarction. The research explored the intervention’s effects on metabolomic parameters and innate immune cell function. This study provided a structured assessment of time-restricted eating as a potential modulator of inflammation and immune cell function in established coronary artery disease.
Article 2: Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859900
Summary: This cross-sectional study found an association between multiple plasma metals and cerebral microbleeds, with detection performed using brain magnetic resonance imaging. The research identified that environmental metal exposure and systemic metal circulation are factors related to cerebrovascular health. This study provided direct data on the connections between various plasma metals and the presence of cerebral microbleeds.
Article 3: Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859899
Summary: A retrospective cohort study of 29281 Korean patients with acute myocardial infarction found that prior antiplatelet exposure was a factor influencing clinical outcomes. The study identified patient cohorts that specifically excluded individuals with pre-existing atrial fibrillation, coronary artery disease, heart failure, cerebrovascular accident, or prior thrombolysis. This research provided concrete findings on how antiplatelet medication history impacts prognosis in an East Asian population, which is characterized by distinct antithrombotic response profiles.
Article 4: Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859898
Summary: The SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism) trial definitively demonstrated the safety of apixaban for thromboprophylaxis in children with heart disease. An exploratory substudy assessed apixaban’s ex vivo effects on surrogate biomarkers of efficacy, including D-dimer, thrombin generation assay parameters, Factor eight, fibrinogen, and protein C. This research provided specific data on apixaban’s impact on coagulation factors and hemostatic proteins in this pediatric patient group.
Article 5: Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41859897
Summary: This study evaluated the real-world relationship between pulmonary vascular resistance and prognosis in Group two pulmonary hypertension, which is defined as pulmonary hypertension caused by left heart disease. Researchers analyzed data from 563 patients across two prospective Japanese multicenter registries, thus establishing specific patient cohorts for this analysis. The investigation assessed the efficacy of emerging therapies within this challenging condition, providing concrete data on therapeutic approaches for patients with left heart disease and pulmonary hypertension.
📝 Transcript
Today’s date is March 21, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Effect of 2 Weeks of Time-Restricted Eating on Innate Immunity and Systemic Inflammation in Patients With a History of Myocardial Infarction: A Randomized-Controlled Crossover Study. A randomized-controlled crossover study investigated a two-week time-restricted eating intervention, allowing eating only between 8 a.m. and 2 p.m., in patients with a history of myocardial infarction. The research explored the intervention’s effects on metabolomic parameters and innate immune cell function. This study provided a structured assessment of time-restricted eating as a potential modulator of inflammation and immune cell function in established coronary artery disease.
Article number two. Association of Multiple Plasma Metals With Cerebral Microbleeds: A Brain Magnetic Resonance Imaging-Based Study. This cross-sectional study found an association between multiple plasma metals and cerebral microbleeds, with detection performed using brain magnetic resonance imaging. The research identified that environmental metal exposure and systemic metal circulation are factors related to cerebrovascular health. This study provided direct data on the connections between various plasma metals and the presence of cerebral microbleeds.
Article number three. Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction. A retrospective cohort study of 29281 Korean patients with acute myocardial infarction found that prior antiplatelet exposure was a factor influencing clinical outcomes. The study identified patient cohorts that specifically excluded individuals with pre-existing atrial fibrillation, coronary artery disease, heart failure, cerebrovascular accident, or prior thrombolysis. This research provided concrete findings on how antiplatelet medication history impacts prognosis in an East Asian population, which is characterized by distinct antithrombotic response profiles.
Article number four. Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy. The SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism) trial definitively demonstrated the safety of apixaban for thromboprophylaxis in children with heart disease. An exploratory substudy assessed apixaban’s ex vivo effects on surrogate biomarkers of efficacy, including D-dimer, thrombin generation assay parameters, Factor eight, fibrinogen, and protein C. This research provided specific data on apixaban’s impact on coagulation factors and hemostatic proteins in this pediatric patient group.
Article number five. Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry. This study evaluated the real-world relationship between pulmonary vascular resistance and prognosis in Group two pulmonary hypertension, which is defined as pulmonary hypertension caused by left heart disease. Researchers analyzed data from 563 patients across two prospective Japanese multicenter registries, thus establishing specific patient cohorts for this analysis. The investigation assessed the efficacy of emerging therapies within this challenging condition, providing concrete data on therapeutic approaches for patients with left heart disease and pulmonary hypertension.
Thank you for listening. Don’t forget to subscribe.
🔍 Keywords
coronary artery disease, Time-restricted eating, pediatric heart disease, clinical outcomes, Korean patients, prognosis, magnetic resonance imaging, pulmonary hypertension, Antiplatelet exposure, D-dimer, emerging therapies, Pulmonary vascular resistance, thromboprophylaxis, cerebral microbleeds, antithrombotic response, environmental exposure, left heart disease, Apixaban, cerebrovascular health, myocardial infarction, acute myocardial infarction, hemostatic biomarkers, innate immunity, Plasma metals, systemic inflammation.
ℹ️ About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • Follow